On November 5, 2020 Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, reported that it will host its second in a series of virtual seminars highlighting the latest data from its HPK1 program (Press release, Nimbus Therapeutics, NOV 5, 2020, View Source [SID1234570008]). The seminar, titled "Novel, Potent, Selective HPK1 Inhibitors Enhance Immune Activation to Inhibit Tumor Growth," will take place on Tuesday, Nov. 17, from 11 a.m. to 12 p.m. ET.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Nimbus’ scientific leadership will present new preclinical data on the anti-tumor immune activity of its small-molecule HPK1 inhibitors. These data are featured in recent poster presentations at the EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium and the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting.
If you wish to attend the live seminar, please pre-register at: Nimbus HPK1 Seminar II. A replay of the webcast will be available at this link after the event.
A recording of Nimbus’ previous HPK1 seminar can be accessed at https://bit.ly/NimbusHPK1Seminar